

해외 바이오의약품 임상 현황 (2019.11.26~2019.12.02)

한국바이오의약품협회, 2019.12.03.
출처: ClinicalTrials.gov

○ 미국 67건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04083183	Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases	Donor Non-Malignant Neoplasm	Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 Drug: Fludarabine Drug: Cyclophosphamide Biological: Lapine T-Lymphocyte Immune Globulin Radiation: Total-Body Irradiation Procedure: Hematopoietic Cell Transplantation Drug: Mycophenolate Mofetil Drug: Sirolimus	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04029038	Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma	CD19 Positive CD22 Positive Minimal Residual Disease Progressive Disease Recurrent B Acute Lymphoblastic Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent Non-Hodgkin Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Non-Hodgkin Lymphoma	Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells Drug: Cyclophosphamide Drug: Fludarabine	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1 Phase 2
NCT04022239	Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant	Allogeneic Hematopoietic Stem Cell Transplant Recipient Donor Hematopoietic and Lymphoid Cell Neoplasm	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Bendamustine Hydrochloride Drug: Cyclophosphamide Biological: Filgrastim-sndz Drug: Fludarabine Drug: Fludalarabine Phosphate Drug: Melphalan Drug: Mycophenolate Mofetil Biological: Rituximab Drug: Tacrolimus Radiation: Total-Body Irradiation	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1 Phase 2
NCT03513458	Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation	Asthma	Biological: Anakinra Other: Anakinra Matching Placebo Drug: Dermatophagoides Farinae	University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI)	Phase 1 Phase 2
NCT03487731	Allogeneic Human Mesenchymal Stem Cell Injection in PATieNts With FaceTogenic Back Pain	Facetogenic Back Pain Back Pain	Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs) Drug: Placebo	Joshua M Hare University of Miami	Phase 1 Phase 2
NCT04077099	REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer	NSCLC	Drug: REGN5093	Regeneron Pharmaceuticals	Phase 1 Phase 2
NCT04044430	Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer	Metastatic Colon Adenocarcinoma Metastatic Colorectal Adenocarcinoma Metastatic Microsatellite Stable Colorectal Carcinoma Metastatic Rectal Adenocarcinoma Stage III Colon Cancer Stage III Colorectal Cancer Stage III Rectal Cancer Stage IIIA Colon Cancer Stage IIIA Colorectal Cancer Stage IIIA Rectal Cancer Stage IIIB Colon Cancer Stage IIIB Colorectal Cancer Stage IIIB Rectal Cancer Stage IIIC Colon Cancer Stage IIIC Colorectal Cancer Stage IIIC Rectal Cancer Stage IV Colon Cancer Stage IV Colorectal Cancer Stage IV Rectal Cancer Stage IVA Colon Cancer Stage IVA Colorectal Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Colorectal Cancer Stage IVB Rectal Cancer Stage IVC Colon Cancer Stage IVC Colorectal Cancer Stage IVC Rectal Cancer	Drug: Binimetinib Drug: Encorafenib Biological: Nivolumab Other: Questionnaire Administration	University of California, San Francisco Array BioPharma Bristol-Myers Squibb (BMS)	Phase 1 Phase 2
NCT04164069	Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab	Advanced Colorectal Carcinoma Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Bevacizumab Drug: Dasatinib Drug: Fluorouracil Drug: Leucovorin Drug: Leucovorin Calcium Drug: Oxaliplatin Other: Quality-of-Life Assessment	Anne Noonan National Cancer Institute (NCI) Ohio State University Comprehensive Cancer Center	Phase 1
NCT04160494	D2C7-IT With Atezolizumab for Recurrent Gliomas	Malignant Glioma	Drug: D2C7-IT (6920 ng/mL via convection-enhanced delivery) Drug: Atezolizumab (1200 mg every three weeks)	Darell D. Bigner, MD, PhD Istari Oncology, Inc. National Cancer Institute (NCI) Genentech, Inc. Duke University	Phase 1
NCT04156828	Copanisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma	Grade 3b Follicular Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Refractory Diffuse Large B-Cell Lymphoma Non-Hodgkin's Lymphoma	Drug: Copanisib Drug: Gemcitabine Drug: Carboplatin Drug: Dexamethasone Biological: Rituximab Biological: Pegfilgrastim	University of Washington National Cancer Institute (NCI) Bayer	Phase 1
NCT04150640	P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric	Esophageal Adenocarcinoma Gastric Adenocarcinoma	Drug: Nal-IRI Drug: Oxaliplatin Drug: 5-FU Drug: Trastuzumab	University of Wisconsin, Madison psen	Phase 2
NCT04148118	A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults	Anthrax	Biological: BW-1010: 50 췡g - sprayer - IN Biological: BW-1010: 50 췡g - pipette - IN Biological: BW-1010: 100 췡g - sprayer - IN Biological: BW-1010: 100 췡g - pipette - IN Biological: Saline (Placebo) - sprayer - IN Biological: Saline (Placebo) - pipette - IN Biological: BioThrax (positive control) - SC	BlueWillow Biologics Porton Biopharma Ltd.	Phase 1
NCT04140162	Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy	Multiple Myeloma	Drug: Daratumumab Drug: Lenalidomide Drug: Bortezomib Drug: Dexamethasone	University of Michigan Rogel Cancer Center Janssen Scientific Affairs, LLC	Phase 2
NCT04131413	HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia	Human Papillomavirus Type 16 Cervical Intraepithelial Neoplasia Grade II Cervical Intraepithelial Neoplasia, Grade III	Drug: pNGVL4aCRTE6E7L2	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI)	Phase 1
NCT04128371	Mepolizumab in Episodic Angioedema With Eosinophilia	Eosinophilia Angioedema	Biological: Nucala (mepolizumab)	National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health Clinical Center (CC)	Phase 2

해외 바이오의약품 임상 현황 (2019.11.26~2019.12.02)

한국바이오의약품협회, 2019.12.03.
출처: ClinicalTrials.gov

NCT04125719	PVSRIP0 in Combination With Nivolumab in Melanoma	Melanoma	Biological: PVSRIP0 Drug: Nivolumab	Darell D. Bigner, MD, PhD Duke University Istari Oncology, Inc. Bristol-Myers Squibb	Phase 1
NCT04120454	Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer	Metastatic Lung Non-Small Cell Carcinoma Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Biological: Pembrolizumab Biological: Ramucirumab	Ohio State University Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04120246	Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 ERBB2 Overexpression HER2 Positive Breast Carcinoma Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 Refractory Breast Carcinoma	Drug: Alpha-tocopheryloxyacetic Acid Biological: Trastuzumab	University of Washington National Cancer Institute (NCI) Veana Therapeutics, Inc.	Phase 1
NCT04117945	Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer	BRAF V600E Negative KRAS Gene Mutation Negative Locally Advanced Unresectable Colorectal Adenocarcinoma Metastatic Colorectal Adenocarcinoma NRAS Gene Mutation Negative Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 Stage IIIC Colorectal Cancer AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Cetuximab Drug: Irinotecan Biological: Panitumumab Drug: Regorafenib	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2
NCT04111172	Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies	Pancreatic Ductal Adenocarcinoma Colorectal Adenocarcinoma Gastric Adenocarcinoma Esophageal Adenocarcinoma	Biological: Ad5.F35-hGCC-PADRE	Thomas Jefferson University	Phase 2
NCT04106362	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma	Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 KRAS Protein Variant Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Biological: Cetuximab Drug: Cisplatin Other: Quality-of-Life Assessment Other: Questionnaire Administration Radiation: Radiation Therapy	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04099797	C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)	Diffuse Intrinsic Pontine Glioma High Grade Glioma	Genetic: (C7R)-GD2.CART cells Drug: Cyclophosphamide Drug: Fludarabine	Baylor College of Medicine Texas Children's Hospital Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintololimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	HLA-A2 Positive Cells Present Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintololimid	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2
NCT04081389	Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer	Anatomic Stage 0 Breast Cancer AJCC v8 Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Early-Stage Breast Carcinoma Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Prognostic Stage 0 Breast Cancer AJCC v8 Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma	Drug: Celecoxib Drug: Cyclophosphamide Drug: Doxorubicin Drug: Doxorubicin Hydrochloride Drug: Paclitaxel Biological: Recombinant Interferon Alfa-2b Drug: Rintololimid	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1
NCT04056910	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors	Advanced Solid Tumor IDH1 Mutation Glioma	Drug: ivosidenib and nivolumab	Jason J. Luke, MD Agiros Pharmaceuticals, Inc. Bristol-Myers Squibb (BMS) University of Pittsburgh	Phase 2
NCT04016116	Dual PD-1 and JAK2 Inhibition in Hematological Malignancies	Cancer Hematological Malignancy	Drug: Pembrolizumab Drug: Ruxolitinib	NYU Langone Health	Phase 2
NCT04003649	IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma	Recurrent Glioblastoma Refractory Glioblastoma	Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR Truncated CD19-expressing Autologous TN/MEM Cells Biological: Ipilimumab Biological: Nivolumab Other: Quality-of-Life Assessment Other: Questionnaire Administration	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03993327	An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer	Colorectal Carcinoma Metastatic in the Liver Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Iodine I 124 Monoclonal Antibody M5A Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03969446	Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory	Acute Myeloid Leukemia High Risk Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent High Risk Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory High Risk Myelodysplastic Syndrome Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia	Drug: Decitabine Biological: Pembrolizumab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03943901	Split-Dose R-CHOP for Older Adults With DLBCL	Diffuse Large B Cell Lymphoma DLBCL Cancer	Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone Biological: Pegfilgrastim	University of Wisconsin, Madison Medical College of Wisconsin	Phase 2
NCT03935594	Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars	Hypertrophic Scar	Biological: PRP Injection Drug: Saline Injection	Vanderbilt University Medical Center	Phase 2
NCT03925532	Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant	Allogeneic Hematopoietic Stem Cell Transplantation Recipient Osteopenia Osteoporosis	Biological: Denosumab	Roswell Park Cancer Institute Amgen	Phase 2
NCT03908840	Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma	Hepatocellular Carcinoma	Biological: TBI 302	Therapure Biopharma Inc	Phase 1

해외 바이오의약품 임상 현황 (2019.11.26~2019.12.02)

한국바이오의약품협회, 2019.12.03.
출처: ClinicalTrials.gov

NCT03872505	Pre-operative Non-Anthracycline Chemotherapy, Durvalumab +/- Radiation Therapy in Triple Negative Breast Cancer	Breast Cancer Triple Negative Breast Cancer	Drug: Durvalumab Radiation: Radiation Therapy Drug: Carboplatin Drug: Paclitaxel	Cedars-Sinai Medical Center AstraZeneca	Phase 2
NCT03820141	Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer	Breast Cancer	Drug: Durvalumab Drug: Trastuzumab Drug: Pertuzumab	Jenny C. Chang, MD AstraZeneca The Methodist Hospital System	Phase 2
NCT03798301	Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells	CMV Infection Cytomegalovirus Infections CMV Viremia Opportunistic Infections	Biological: CMV-specific T-cells	University of Wisconsin, Madison University of Wisconsin Program for Advanced Cell Therapy (PACT) University of Wisconsin Carbone Cancer Center (UWCCC) University of Wisconsin School of Medicine and Public Health (UWSPH) UW Health	Phase 1
NCT03751709	Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL	B-Cell Acute Lymphoblastic Leukaemia ALL, Adult B-ALL	Drug: Blinatumomab Other: Haplo-Mismatched Cell Therapy (HMCT)	Cedars-Sinai Medical Center Amgen	Phase 1
NCT03679624	Daratumumab Plus Ibrutinib in Patients With Waldenström's Macroglobulinemia	Waldenstrom Macroglobulinemia Waldenstrom's Disease Waldenström; Hypergammaglobulinemia Waldenstrom's Macroglobulinemia Recurrent Waldenstrom's Macroglobulinemia of Lymph Nodes Waldenstrom's Macroglobulinaemia, Without Mention of Remission Waldenstrom's Macroglobulinemia Refractory	Drug: Ibrutinib Drug: Daratumumab	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC Mayo Clinic	Phase 2
NCT03639324	Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL	Chronic Lymphocytic Leukemia CLL Relapsed CLL Refractory Chronic Lymphocytic Leukemia Relapsed Chronic Lymphocytic Leukemia	Drug: Rituximab, Idelalisib, and Venetoclax	Virginia Commonwealth University	Phase 1
NCT03579888	CD19+ Specific Chimeric Antigen Receptor T Cells in Treating Participants With CD19+ Lymphoid Malignancies	Acute Lymphoblastic Leukemia Blasts More Than 5 Percent of Bone Marrow Nucleated Cells Blasts More Than 5 Percent of Peripheral Blood White Cells CD19 Positive Chronic Lymphocytic Leukemia Minimal Residual Disease Non-Hodgkin Lymphoma Small Lymphocytic Lymphoma	Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER11 T Cells Drug: Cyclophosphamide Drug: Fludarabine	M.D. Anderson Cancer Center Ziopharm Oncology	Phase 1
NCT03531242	Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults	Venezuelan Equine Encephalomyelitis	Biological: 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1	U.S. Army Medical Research and Development Command	Phase 2
NCT03527108	Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC	Non Small Cell Lung Cancer	Drug: Nivolumab, ramucirumab Drug: Nivolumab	Fox Chase Cancer Center Bristol-Myers Squibb Eli Lilly and Company	Phase 2
NCT03426826	The Gut-Brain Study	Autism Spectrum Disorder (ASD) Gastro-Intestinal Disorder	Biological: FMT versus placebo	Children's Hospital Los Angeles	Phase 1
NCT03058068	Human Mesenchymal Stem Cells Infusion in Patients With Cystic Fibrosis	Cystic Fibrosis	Biological: Allo-hMSCs Biological: Placebo	Joshua M Hare University of Miami	Phase 1
NCT03014804	Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma	Giant Cell Glioblastoma Gliosarcoma Oligodendroglioma Recurrent Glioblastoma Small Cell Glioblastoma	Biological: autologous dendritic cells pulsed with tumor lysate antigen vaccine Other: Laboratory Biomarker Analysis Biological: Nivolumab Other: Quality-of-Life Assessment Other: Questionnaire Administration	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI) Northwest Biotherapeutics Bristol-Myers Squibb	Phase 2
NCT02677350	Allogeneic Human Mesenchymal Stem Cells (hMSC) in Patients With Fistulizing Crohn's Disease Via Perifistula Injections (GALENE)	Crohn's Disease Fistulizing Crohn's Disease Stem Cells	Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)	Joshua M Hare University of Miami	Phase 1
NCT02434965	Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy	Severe Hypoxic-ischemic Encephalopathy	Drug: HPDSC Drug: Cord blood	New York Medical College Celgene	Phase 2
NCT04166487	Plasma-Adapted First-Line Pembrolizumab in NSCLC	NSCLC Stage IV Metastatic Non-Small Cell Lung Cancer	Drug: Pembrolizumab Drug: PEMETREXED Drug: CARBOPLATIN Drug: PACLITAXEL Diagnostic Test: InVision	Dana-Farber Cancer Institute Inivata	Phase 2
NCT04164979	Phase II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma	Gastric Adenocarcinoma Gastroesophageal Cancer	Drug: Cabozantinib Drug: Pembrolizumab	University of California, Irvine Exelixis	Phase 2
NCT04007588	A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma	Melanoma Stage III Melanoma Stage IV	Drug: Nivolumab Drug: BMS-986205 Drug: Ipilimumab	Dana-Farber Cancer Institute Bristol-Myers Squibb	Phase 2
NCT03993106	A Study of sEphB4-HSA in Kaposi Sarcoma	Kaposi Sarcoma	Drug: sEphB4-HSA	Vasgene Therapeutics, Inc	Phase 2
NCT03956056	Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy	Pancreas Cancer Pancreatic Cancer Cancer of the Pancreas	Biological: Neoantigen Peptide Vaccine Drug: Poly ICLC Procedure: Blood for immune monitoring	Washington University School of Medicine National Institutes of Health (NIH) National Cancer Institute (NCI)	Phase 1
NCT03880656	BM-MNCs for Lower Extremity Compartment Syndrome Injury	Compartment Syndrome Traumatic Lower Extremity	Biological: Intramuscular administration of autologous BM-MNCs	Oregon Health and Science University University of Pittsburgh	Phase 1
NCT04129151	Palbociclib + Ganitumab in Ewing Sarcoma	Ewing Sarcoma Ewing's Sarcoma Recurrent	Drug: Palbociclib Drug: Ganitumab	Dana-Farber Cancer Institute 1 Million 4 Anna Foundation Carson Sarcoma Foundation Teaming up to Fight Childhood Cancer ChemoWarrior: the elisidler foundation i-ROK Foundation Rutledge Cancer Foundation Alan B. Slifka Foundation	Phase 2

해외 바이오의약품 임상 현황 (2019.11.26~2019.12.02)

한국바이오의약품협회, 2019.12.03.
출처: ClinicalTrials.gov

NCT03814798	Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency	Primary Immunodeficiency	Biological: IGSC 20% daily push versus every 2 weeks pump Biological: IGSC 20% daily push versus once a week pump Biological: IGSC 20% daily push versus 2 times per week pump Biological: IGSC 20% 150 mg/kg	Grifols Therapeutics LLC	Phase 3
NCT04167696	Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02	Acute Myeloid Leukemia Myelodysplastic Syndrome	Biological: CYAD-02 Drug: ENDOXAN Drug: Fludara	Celyad (formerly named Cardio3 BioSciences)	Phase 1
NCT03818854	Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome	Respiratory Distress Syndrome, Adult	Biological: Human Mesenchymal Stromal Cells Biological: Cell Reconstitution Media	Michael A. Matthay United States Department of Defense Harborview Injury Prevention and Research Center Oregon Health and Science University Vanderbilt University Medical Center The University of Texas Health Science Center, Houston University of Minnesota University of California, San Francisco	Phase 2
NCT04165031	A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation	Advanced Solid Tumor Non-Small Cell Lung Cancer Colorectal Cancer	Drug: LY3499446 Drug: Abemaciclib Drug: Cetuximab Drug: Erlotinib Drug: Docetaxel	Eli Lilly and Company	Phase 1 Phase 2
NCT04173819	Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults	HIV-1-infection	Biological: 3BNC117-LS-J Biological: 10-1074-LS-J Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1 Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2 Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3 Biological: Placebo	International AIDS Vaccine Initiative University of Washington Rockefeller University	Phase 1 Phase 2
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	Non-alcoholic Steatohepatitis	Drug: Placebo Drug: BFKB8488A	Genentech, Inc.	Phase 2
NCT03989206	Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis	Moderate-to-Severe Atopic Dermatitis	Drug: Nemolizumab	Galderma R&D	Phase 3
NCT04143659	A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception	Healthy Women Female Contraception	Biological: levonorgestrel butanoate (LB) injection	Health Decisions Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1
NCT03816397	Adalimumab in JIA-associated Uveitis Stopping Trial	Uveitis JIA	Biological: Adalimumab Other: Placebo	Nisha Acharya Children's Hospital of Philadelphia Children's Hospital Medical Center, Cincinnati Children's Mercy Hospital Kansas City National Eye Institute (NEI) Great Ormond Street Hospital for Children NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust Alder Hey Children's NHS Foundation Trust Johns Hopkins University Children's Hospital Los Angeles Seattle Children's Hospital Newcastle-upon-Tyne Hospitals NHS Trust University Hospital Southampton NHS Foundation Trust Sheffield Children's NHS Foundation Trust The Royal Children's Hospital University of California, San Francisco	Phase 3
NCT03739996	Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1	HIV Infections	Drug: Oral Cabotegravir (CAB) Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Drug: Long-Acting Injectable Cabotegravir (CAB LA) Biological: VRC07-523LS Drug: Standard of Care (SOC) Oral ART	National Institute of Allergy and Infectious Diseases (NIAID) ViiV	Phase 2
NCT04178902	A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory Multiple Myeloma	Multiple Myeloma (MM) Cancer	Drug: ABBV-467	AbbVie	Phase 1

해외 바이오의약품 임상 현황 (2019.11.26~2019.12.02)

한국바이오의약품협회, 2019.12.03.
출처: ClinicalTrials.gov

NCT04182204	A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-Cell Lymphoma	Drug: Polatuzumab Vedotin Drug: Rituximab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multi-peptide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1 Phase 2

○ 영국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04166721	WaKING: Wnt and checkPoint INhibition in Gastric Cancer	Metastatic Esophageal Cancer Metastatic Gastric Cancer	Drug: Atezolizumab	Royal Marsden NHS Foundation Trust	Phase 1 Phase 2
NCT03816397	Adalimumab in JIA-associated Uveitis Stopping Trial	Uveitis JIA	Biological: Adalimumab Other: Placebo	Nisha Acharya Children's Hospital of Philadelphia Children's Hospital Medical Center, Cincinnati Children's Mercy Hospital Kansas City National Eye Institute (NEI) Great Ormond Street Hospital for Children NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust Alder Hey Children's NHS Foundation Trust Johns Hopkins University Children's Hospital Los Angeles Seattle Children's Hospital Newcastle-upon-Tyne Hospitals NHS Trust University Hospital Southampton NHS Foundation Trust Sheffield Children's NHS Foundation Trust The Royal Children's Hospital University of California, San Francisco	Phase 3
NCT04182204	A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-Cell Lymphoma	Drug: Polatuzumab Vedotin Drug: Rituximab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3

○ 프랑스 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03949881	Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency	Total Bilateral Limbal Cell Deficiency	Biological: FEMJA transplantation	Hospices Civils de Lyon	Phase 1 Phase 2
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multi-peptide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1 Phase 2

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04116658	First-in-Human, Phase 1b/2a Trial of a Multi-peptide Therapeutic Vaccine in Patients With Progressive Glioblastoma	Glioblastoma, Adult	Biological: Multiple dose of EO2401	Enterome Covance	Phase 1 Phase 2
NCT04182204	A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Diffuse Large B-Cell Lymphoma	Drug: Polatuzumab Vedotin Drug: Rituximab Drug: Gemcitabine Drug: Oxaliplatin	Hoffmann-La Roche	Phase 3

○ 중국 15건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04172454	Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors	Advanced Solid Tumors Melanoma	Biological: AK104	Akeso Akeso Pharmaceuticals, Inc.	Phase 1 Phase 2
NCT04146298	Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer	Pancreatic Cancer Pancreatic Neoplasms Pancreatic Ductal Adenocarcinoma Advanced Cancer	Drug: Cyclophosphamide Drug: Fludarabine Biological: Mutant KRAS G12V-specific TCR transduced autologous T cells Drug: Anti-PD-1 monoclonal antibody	Guo ShiWei Providence Cancer Center, Earle A. Childs Research Institute Changhai Hospital	Phase 1 Phase 2
NCT03867370	Toripalimab or Placebo as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma	Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma	Biological: TORIPALIMAB INJECTION(JS001)	Shanghai Junshi Bioscience Co., Ltd.	Phase 1 Phase 2
NCT04165174	PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT	HCC	Drug: Terepril monoclonal antibody; Apatinib Radiation: SBRT	Huazhong University of Science and Technology	Phase 2
NCT04163237	Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer	Advanced Liver Cancer	Drug: PD-1 Drug: Sorafenib	Guangxi Medical University	Phase 3

해외 바이오의약품 임상 현황 (2019.11.26~2019.12.02)

한국바이오의약품협회, 2019.12.03.
출처: ClinicalTrials.gov

NCT04162327	A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor	Advanced Solid Tumor	Drug: IBI315	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04156217	EBV-TCR-T Cells for EB Virus Infection After HSCT	EBV Emia and EBV Positive PTLD After Allogenic HSCT	Biological: EBV-TCR-T cells	Hebei Yanda Ludaopei Hospital China Immunotech Co., Ltd.	Phase 1
NCT04153279	CMV-TCR-T Cells for CM Virus Infection After HSCT	CMV Infection or Reactivation After Allogenic HSCT	Biological: CMV-TCR-T cells	Hebei Yanda Ludaopei Hospital China Immunotech Co., Ltd.	Phase 1
NCT04074408	Intracavitary Injection of hUMSCs in Acute Basal Ganglia Hematoma After Stereotactic Aspiration	Basal Ganglia Hematoma	Procedure: stereotactic surgery Biological: hUMSCs Biological: placebo	Second Affiliated Hospital, School of Medicine, Zhejiang University The First Affiliated Hospital, University of Science and Technology of China Huzhou Hospital, School of Medicine, Zhejiang University First Affiliated Hospital of Fujian Medical University Jinhua Hospital, School of Medicine, Zhejiang University Taizhou Hospital	Phase 2
NCT04030533	Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants	Healthy	Drug: Guselkumab (SC): Dose 1 Drug: Guselkumab (SC): Dose 2 Drug: Guselkumab (IV): Dose 1 Drug: Guselkumab (IV): Dose 2 Drug: Ustekinumab 6 mg/mL	Janssen Research & Development, LLC	Phase 1
NCT04026100	CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma	Diffuse Large B-cell Lymphoma	Biological: CTA101	The First Affiliated Hospital with Nanjing Medical University Nanjing Bioheng Biotech Co., Ltd.	Phase 1
NCT04173793	A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)	Heterozygous Familial Hypercholesterolemia	Drug: AK102 Drug: Placebo Drug: Statins and/or Ezetimibe	Akeso AD Pharmaceuticals Co., Ltd. (Guangzhou)	Phase 2
NCT04173637	Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis	Plaque Psoriasis	Biological: AK101 Biological: Placebo	Akeso Akeso Tiancheng, Inc	Phase 2
NCT02585908	Safety and Efficacy of 款灌 T Cell Against Gastric Cancer	Gastric Cancer	Biological: CIK Biological: 款灌 T Biological: CIK and 款灌 T	Beijing Doing Biomedical Co., Ltd.	Phase 1 Phase 2
NCT04093752	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)	Type 2 Diabetes	Drug: Tirzepatide Drug: Insulin Glargine	Eli Lilly and Company	Phase 3